Table 1.
Phase III trials of targeted therapy in advanced renal cell carcinoma
| Agent | Trial | Size | Percent poor risk | Overall PFS (95% CI) | Overall response rate (95% CI) | Overall disease control rate |
|---|---|---|---|---|---|---|
| Sunitinib | Motzer 200737 | N = 750 | 6.4% | 11 months (10–12) | 31% (26–36) | 79% |
| Sorafenib | Escudier 200757 | N = 903 | 0% | 5.5 months | 10% (7–13) | 62% (57–66) |
| Temsirolimus | Hudes 200735 | N = 626 | 74% | 5.5 months (3.9–7.0) | 8.6% (4.8–12.4) | 32.1% (25.7–38.4) |
| Everolimus | Motzer 200836 | N = 410 | 15% | 4.0 months (3.7–5.5) | 1% | 64% |
| Bevacizumab/IFN | Escudier 200738 | N = 649 | 9% | 10.2 months | 31% | 77% |
| Bevacizumab/IFN | Rini 200839 | N = 732 | 10% | 8.5 months (7.5–9.7) | 25.5% (20.9–30.6) |